Company intelligence / Profile preview

MosquitoMate

Lexington, Kentucky, USA

Ownership: Private
Employees: ~22
Development stage: Other

Overview

MosquitoMate's ZAP male technology achieved EPA registration in 2017 and demonstrated 95.5% reduction in Aedes aegypti populations in the Debug Fresno trial published in April 2020. The product is commercially available for home and institutional use in 20 states and Washington D.C.

Therapeutic areas: Infectious Diseases
Modalities: Biological control agentLive biotherapeutic product therapy
Industry: Non-Drug Biotech

Partnerships

Verily (Alphabet Inc.)Consolidated Mosquito Abatement District (Fresno, CA)Florida Keys Mosquito Control DistrictUniversity of Kentucky

Beyond the preview

Go deeper on MosquitoMate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MosquitoMate.

Explore the full profile